Ionis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024. In the quarter to June 2026, revenue fell 40.7%, EPS fell 188.5%, free cash flow grew 299.3% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IONS
Ionis Pharmaceuticals, Inc. (IONS) Piotroski F-score
Ionis Pharmaceuticals, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 2.00 |
| FY2024 | 2 | (2.00) |
| FY2023 | 4 | 3.00 |
| FY2022 | 1 | (5.00) |
| FY2021 | 6 | 2.00 |
| FY2020 | 4 | (2.00) |
| FY2019 | 6 | 0.00 |
| FY2018 | 6 | 0.00 |
| FY2017 | 6 | 3.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (11.69%) | (15.15%) | Fail | 0 |
| Positive operating cash flow | (268.58m) | (500.95m) | Fail | 0 |
| Rising return on assets | (11.69%) | (15.15%) | Pass | 1 |
| Cash flow above net income | 112.80m | (47.05m) | Pass | 1 |
| Falling long-term leverage | 0.41 | 0.42 | Pass | 1 |
| Rising current ratio | 3.83 | 8.47 | Fail | 0 |
| No new shares issued | 160,010,000 | 149,514,000 | Fail | 0 |
| Rising gross margin | 98.31% | 98.41% | Fail | 0 |
| Rising asset turnover | 0.29 | 0.24 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 5 |
| AXSM Axsome Therapeutics, Inc. compare | 5 |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 5 |
| IONS Ionis Pharmaceuticals, Inc. | 4 |
| IOVA Iovance Biotherapeutics, Inc. compare | 4 |
| SYRE Spyre Therapeutics, Inc. compare | 3 |
| ABVX Abivax SA Sponsored ADR compare | — |
| PRAX Praxis Precision Medicines, Inc. compare | — |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover